Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|April 11, 2022
Doses, fractionations, constraints for stereotactic radiotherapySimona Borghesi, Cynthia Aristei, Francesco Marampon
International Journal of Molecular Sciences|May 26, 2019
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to RadiationFrancesco Marampon, Carmela Ciccarelli, Bianca Maria Zani
Molecular Cancer|August 11, 2006
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumorsFrancesco Marampon, Carmela Ciccarelli, Bianca M Zani
International Journal of Molecular Sciences|June 13, 2018
Cellular and Molecular Mediators of Bone Metastatic LesionsGiulia Battafarano, Michela Rossi, Francesco Marampon, et al.
Molecular Pharmacology|March 8, 2017
The First Negative Allosteric Modulator for Dopamine D<sub>2</sub> and D<sub>3</sub> Receptors, SB269652 May Lead to a New Generation of Antipsychotic DrugsMario Rossi, Irene Fasciani, Francesco Marampon, et al.
Frontiers in Cell and Developmental Biology|March 2, 2026
From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatmentElisa Macrì, Marika Attili, Franco Locatelli, et al.
Drug Design, Development and Therapy|March 11, 2017
Defective DNA repair mechanisms in prostate cancer: impact of olaparibFrancesca De Felice, Vincenzo Tombolini, Francesco Marampon, et al.
International Journal of Molecular Sciences|February 15, 2020
Bone Control of Muscle FunctionGiulia Battafarano, Michela Rossi, Francesco Marampon, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2018
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell linesSilvia Codenotti, Maura Poli, Michela Asperti, et al.
Oncotargets and Therapy|July 17, 2019
Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitationsSilvia Codenotti, Walaa Mansoury, Luca Pinardi, et al.
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|April 11, 2022
Doses, fractionations, constraints for stereotactic radiotherapySimona Borghesi, Cynthia Aristei, Francesco Marampon
International Journal of Molecular Sciences|May 26, 2019
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to RadiationFrancesco Marampon, Carmela Ciccarelli, Bianca Maria Zani
Molecular Cancer|August 11, 2006
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumorsFrancesco Marampon, Carmela Ciccarelli, Bianca M Zani
International Journal of Molecular Sciences|June 13, 2018
Cellular and Molecular Mediators of Bone Metastatic LesionsGiulia Battafarano, Michela Rossi, Francesco Marampon, et al.
Molecular Pharmacology|March 8, 2017
The First Negative Allosteric Modulator for Dopamine D<sub>2</sub> and D<sub>3</sub> Receptors, SB269652 May Lead to a New Generation of Antipsychotic DrugsMario Rossi, Irene Fasciani, Francesco Marampon, et al.
Frontiers in Cell and Developmental Biology|March 2, 2026
From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatmentElisa Macrì, Marika Attili, Franco Locatelli, et al.
Drug Design, Development and Therapy|March 11, 2017
Defective DNA repair mechanisms in prostate cancer: impact of olaparibFrancesca De Felice, Vincenzo Tombolini, Francesco Marampon, et al.
International Journal of Molecular Sciences|February 15, 2020
Bone Control of Muscle FunctionGiulia Battafarano, Michela Rossi, Francesco Marampon, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2018
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell linesSilvia Codenotti, Maura Poli, Michela Asperti, et al.
Oncotargets and Therapy|July 17, 2019
Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitationsSilvia Codenotti, Walaa Mansoury, Luca Pinardi, et al.
Pageof 16